These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 16837676)

  • 1. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
    N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
    Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons from RUTH.
    Pines A
    Climacteric; 2006 Oct; 9(5):323-4. PubMed ID: 17000580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
    Barrett-Connor E; Cauley JA; Kulkarni PM; Sashegyi A; Cox DA; Geiger MJ
    J Bone Miner Res; 2004 Aug; 19(8):1270-5. PubMed ID: 15231013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
    Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
    J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Raloxifene on all-cause mortality.
    Grady D; Cauley JA; Stock JL; Cox DA; Mitlak BH; Song J; Cummings SR
    Am J Med; 2010 May; 123(5):469.e1-7. PubMed ID: 20399327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
    Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
    J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of raloxifene by vertebral fracture status.
    Sontag A; Wan X; Krege JH
    Curr Med Res Opin; 2010 Jan; 26(1):71-6. PubMed ID: 19908937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene use in clinical practice: efficacy and safety.
    Goldstein SR; Duvernoy CS; Calaf J; Adachi JD; Mershon JL; Dowsett SA; Agnusdei D; Stuenkel CA
    Menopause; 2009; 16(2):413-21. PubMed ID: 19092711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-benefit profiles of raloxifene for women.
    Stefanick ML
    N Engl J Med; 2006 Jul; 355(2):190-2. PubMed ID: 16837684
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Raloxifene (Celvista, Evista)].
    Body JJ; Sternon J
    Rev Med Brux; 2000 Feb; 21(1):35-41. PubMed ID: 10748686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
    Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E
    Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.